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Abstract. As potential regulators of DNA accessibility and activity, epigenetic modifications offer a mechanism by which the
environment can moderate the effects of genes. To date, however, there have been relatively few studies assessing epigenetic
modifications associated with post-traumatic stress disorder (PTSD). Here we investigate PTSD-associated methylation differ-
ences in 33 genes previously shown to differ in whole blood-derived gene expression levels between those with vs. without the
disorder. Drawing on DNA samples similarly obtained from whole blood in 100 individuals, 23 with and 77 without lifetime
PTSD, we used methylation microarray data to assess whether these 33 candidate genes showed epigenetic signatures indicative
of increased risk for, or resilience to, PTSD. Logistic regression analyses were performed to assess the main and interacting
effects of candidate genes’ methylation values and number of potentially traumatic events (PTEs), adjusting for age and other
covariates. Results revealed that only one candidate gene –MAN2C1– showed a significant methylation x PTE interaction, such
that those with both higherMAN2C1methylation and greater exposure to PTEs showed a marked increase in risk of lifetime
PTSD (OR 4.35, 95% CI: 1.07, 17.77,p = 0.04). These results indicate thatMAN2C1methylation levels modify cumulative
traumatic burden on risk of PTSD, and suggest that both gene expression and epigenetic changes at specific loci are associated
with this disorder.
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1. Introduction
The term “epigenetics” refers to the regulation of
genetic functions mediated through mechanisms that
are independent of DNA sequences. Although multi-
ple types of epigenetic modifications have been identi-
fied [1], all involve chemical modifications that regulate
chromatin structure and/or DNA accessibility, which in
turn alters the transcriptional activity of the surround-
ing loci. Epigenetic factors have been the focus of
increasing interest among those interested in studying
mental illness [2], including post-traumatic stress dis-
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order (PTSD) [3–5]. This interest may be due in part
to the relatively few genes that have been conclusively
shown to contribute to risk of common mood-anxiety
disorders (e.g. [6,7]), and the mounting evidence that
epigenetic marks can change in response to external
experiences [8,9]. Indeed, as potential regulators of
DNA accessibility and activity, epigenetic factors may,
through influences on gene expression, offer one mech-
anism by which the environment can moderate the ef-
fects of genes [10]. In addition, epigenetic mecha-
nisms may be involved in the mediation of some gene-
environment (G× E) interactions, such that individu-
als with particular genotype/epigenotypecombinations
may be especially inclined toward mental illness in the
presence of specific environmental exposures. For ex-
ample, numerous studies investigating variation in the
serotonin transporter promoter (5HTTLPR) locus have
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demonstrated that carriers of the short allele are more
susceptible to depression following exposure to stress-
ful life experiences (reviewed in [11]). Thes allele, in
turn, has recently been associated with increased de-
pressive symptoms in adolescents, but only among in-
dividuals who also showed relatively high methylation
levels at this locus [12]. More broadly, in the case of
PTSD, epigenetic effects offer a plausible way in which
an environmental exposure (i.e. potentially traumatic
event, PTE) may modify biological substrates (i.e. gene
expression) in a manner that may increase risk of an
adverse psychopathological outcome [4].
Although epigenetic studies of mental illness have
been growing in number in recent years (reviewed
in [2]), studies focused specifically on PTSD are still
few in number. Animal models of PTSD have iden-
tified epigenetic differences that can discern rats with
PTSD-like vs. non-PTSD-like behaviors, using a vali-
dated PTSD rat model [13]. In this model, rats are ex-
posed to a predator stimulus (cat scent carried on soiled
litter) which serves as the PTE; seven days following
the stress exposure, animals are classified as exhibiting
PTSD-like and non-PTSD-like behavior according to
their performance on behavioral tests (elevated pulse-
maze and acoustic startle response [14]). Assessment
of methylation changes in brain tissue following this
stress paradigm identified some loci (e.g.Dlgap2) that
showed PTSD-associated changes in both methylation
and gene expression patterns in postmortem hippocam-
pal tissue [15]. Interestingly, in this study a significant
correlation was observed betweenDlgap2gene expres-
sion and the degree of behavioral stress responses in in-
dividual rats, suggesting that this locus may contribute
to the molecular substrate of traumatic stress adaptation
in these animals [15]. Another recent study focusing
on humans found that those with lifetime PTSD were
distinguished by methylation profiles suggesting an up-
regulation of genes involved in immune system-related
genes, and a relative downregulation of genes involved
in neurogenesis and the startle response [16]. In the
latter, human-based case, however, the reported PTSD-
associated epigenetic differences were only hypothe-
sized to be associated with downstream differences in
gene expression.
A small but growing literature has provided evidence
for gene expression patterns that distinguish between
those with vs. without PTSD. The majority of these
microarray-based studies have assessed gene expres-
sion changes in RNA derived from either peripher-
al blood mononuclear cells (PBMCs) or whole blood.
The earliest work assessed PTSD-associated gene ex-
pression signatures among trauma survivors admitted
to the emergency room immediately following a trau-
matic event [17]. Bioinformatic functional analyses of
transcripts that were differentially expressed (n = 656)
between the two groups showed a reduced expression
of transcriptional enhancers, distinct expression signa-
tures of transcripts involved in immune activation, and
a significant enrichment of genes that encode neural
and endocrine proteins [17]. A more recent study used
a custom-made “stress/immune” cDNA microarray to
assess expression levels of 384 genes among PTSD-
affected and –unaffected individuals using RNA ob-
tained from whole blood [18]. Of note in this study,
all of the PTSD-affected individuals had been exposed
to the same traumatic event almost 20 years prior to
testing – the Ramstein air show catastrophe of 1989 –
yet typical PTSD symptoms persisted in this group.
Analyses showed a total of 19 differentially expressed
transcripts, five and 14 of which were up- and down-
regulated, respectively [18]. The majority of down-
regulated transcripts (which were the focus of the study)
were associated with immune functions or with reac-
tive oxygen species. Most recently, Yehuda and col-
leagues reported whole blood-derived gene expression
levels among PTSD-affected and –unaffected individ-
uals who had had exposure to the 9/11 attack on New
York City [19]. Differential expression was detect-
ed in 16 distinct genes, several of which are involved
in signal transduction, brain and immune cell func-
tion and HPA axis activity. Of note, although sever-
al genes in this study had previously been linked to
PTSD and/or stress-related outcomes (e.g.FKBP5[20,
21], MHC Class II[22]), the gene showing the largest
difference in expression was mannosidase, alpha, class
2C, member 1 (MAN2C1), a locus that had not previ-
ously been linked to PTSD.
Collectively, these few early studies suggest that in-
vestigations of genome-wide gene expression and epi-
genetic differences associated with PTSD may help to
shed light on the molecular underpinnings of this dis-
order. Among these early studies, however, there are as
yet no reports ofbothgene expression and epigenetic
signatures that characterize PTSD in humans. Here we
build on the extant literature that reports results from
large-scale, gene expression and epigenetic investiga-
tions of PTSD in humans. More specifically, we assess
whether genes previously identified as showing PTSD-
associated gene expression patterns may also show epi-
genetic signatures indicative of increased risk for, or
resilience to, PTSD. The goal of this work was to con-
duct a secondary data analysis of the extant PTSD-
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associated genomic data in order to build a platform
for future studies that assess both gene expression and
epigenetic differences associated with PTSD from the
same individuals, in the same tissues. Since epigenetic
variation occurs in a tissue-specific fashion [23], we fo-
cused on the two studies that assessed gene expression
in peripheral whole blood [18,19], consistent with the
starting material of PTSD-associated epigenetic signa-
tures reported in a previous recent study [16]. Further-
more, we focused our analyses on the potential inter-
action between methylation values of these candidate
genes and cumulative traumatic burden, in order to in-
vestigate more fully the complex ways in which inter-
nal (molecular) and external (PTE) factors may modi-
fy risk for this mental illness and result in phenotypic
variation following trauma exposure [24].
2. Methods and materials
2.1. Participants
This study is based on samples obtained from par-
ticipants in the Detroit Neighborhood Health Study
(DNHS). The DNHS is a study of adults, 18 years or
older, from the Detroit population. A probability sam-
ple of 1,547 households within the city limits of De-
troit was initially chosen and one individual per house-
hold was then randomly selected for a telephone in-
terview. Participants were administered a 40-minute
assessment which included questions on exposure to
traumatic events, socio-demographic and behavioral
characteristics, and a standardized assessment of post-
traumatic stress disorder (PTSD). A subsample of eligi-
ble participants during wave 1 of the study consented to
provide blood specimens by way of venipuncture (n =
501). Wave one samples were collected principally
to assess immune function, and preservation of RNA
for gene expression testing was not included in wave
1 biospecimen collection efforts. For the purposes of
this study, 100 of these 501 participants were selected
midway through the wave 1 sample collection effort in
order to conduct exploratory, pilot testing of epigenetic
profiles associated with mental illness in community-
based settings.
Wave 1 survey participants were representative of
the Detroit population in terms of age, gender, race, in-
come, and educational attainment [25]. The 100 partic-
ipants in the current study were similar to the full sam-
ple on these key sociodemographic characteristics but
were, on average, slightly younger than individuals in
the full survey sample (45.3 vs. 50.6 years,p = 0.003).
Since our subsample of 100 participants for this study
was selected specifically according to presence of men-
tal illness, the prevalence of lifetime PTSD is higher in
our study sample (23%) than in the full survey sample
(14.4%). The DNHS was approved by the Institutional
Review Board at the University of Michigan. More
details regarding this study can be found in [16].
2.2. Assessment of lifetime post-traumatic stress
disorder
Individual assessment of PTSD symptoms was con-
ducted using the PTSD checklist (PCL-C) [26], a 17-
item self-report measure of Diagnostic and Statisti-
cal Manual of Mental Disorders (DSM-IV) [27] PTSD
symptoms, augmented by additional questions about
duration, timing, and impairment or disability due to
the symptoms. Participants were initially asked to iden-
tify PTEs that they experienced in the past from a list
of 19 events that had previously been implemented in
an earlier epidemiologic study to assess PTSD in the
Detroit area [28], and an additional question that al-
lowed the participant to briefly describe any other ex-
traordinarily stressful situation or event. We then asked
those participants who had experienced at least one
traumatic event to choose which one they considered
to be the worst. Participants rated each of the 17 PTSD
symptoms on a scale indicating the degree to which the
respondent had been bothered by a particular symp-
tom as a result of this trauma from 1 (not at all) to 5
(extremely) in reference to this event. An additional
PTSD section assessed symptoms based on a randomly
chosen traumatic event (excluding the worst event) for
those participants who had experienced more than one
PTE. Respondents were considered affected by lifetime
PTSD if all six DSM-IV criteria were met in reference
to either the worst or the random event.
To validate our identification of PTSD obtained from
the telephone interview responses, we conducted clin-
ical in-person interviews among a random subsample
of 51 participants. A licensed clinician conducted one-
hour clinical interviews after obtaining signed consent
from participants, utilizing the Clinician-Administered
PTSD Scale for DSM-IV (CAPS) for PTSD. The coun-
selor was blinded to the information obtained from the
participants during the telephone interview. Partici-
pants received $50 for participation in this part of the
study. Analysis of data from the in-person interviews
showed that the PCL-C used during the telephone in-
terviews had excellent internal consistency and high
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concordance. The PCL-C yielded a Cronbach coeffi-
cient alpha (α) of 0.93. Using clustering scoring based
on DSM-IV criteria (i.e. to be a case, the participant’s
symptoms had to meet all six criteria), the instrument
had a sensitivity (SE) of 0.24, specificity (SP) of 0.97,
positive predictive value (PPV) of 0.80, negative pre-
dictive value (NPV) 0.72, and an area under the ROC
curve (AUC) of 0.76. Low sensitivity values imply that
our survey-based PTSD prevalence estimates are con-
servative. Importantly, the high specificity insures our
PTSD group is made of true cases. All 100 individuals
included in this pilot study were exposed to at least
one PTE; among these, 23 were PTSD-affected and 77
were –unaffected.
2.3. Assessment of additional demographic and
behavioral information
Additional demographic and behavioral information
including age, race/ethnicity, drinking and smoking
was assessed during the telephone portion of the DNHS
survey. Socioeconomic status (SES) was assessed via
self-report according to whether participants had at-
tained high school equivalency or greater (high SES)
or less than high school (low SES). Venipuncture spec-
imens were obtained from consenting participants by
trained phlebotomists during home visits, at which time
the use of any medication was noted on a specimen col-
lection log. Peripheral blood mononuclear cells (PBM-
Cs) were isolated via Ficoll-gradient centrifugation of
whole blood and re-suspended in 6ml of freezing medi-
um, 1ml of which was loaded into a packed cell volume
(PCV) tube and centrifuged the tube at 2400RCF for
1 minute. PCV tubes were then assessed for PBMC
count using the TPP Easy Read Ruler from MIDSCI
(St. Louis, MO) and following manufacturer’s recom-
mended protocols.
2.4. Microarray analyses
Bisulfite conversion of whole blood-derived DNA
samples was performed using the EZ-96 DNA methy-
lation kit from Zymo Research (Orange, CA). One
microgram (µg) of each sample (including controls)
was subjected to bisulfite conversion following manu-
facturer’s recommended protocol. Experimental con-
trols included replicates for two samples to assess vari-
ation throughout the experimental process (i.e. from
initial bisulfite conversion through microarray analy-
sis), as well as one sample of completely unmethylated
and completely methylated human DNA, commercial-
ly available through Zymo Research, in each of the two
96 well plates used in the bisulfite conversion step. All
control replicates were placed on separate microarray
chips, and the remaining samples were assigned to mi-
croarray chips at random, without regard to PTSD sta-
tus. Bisulfite converted DNA samples were subjected
to methylation profiling via the humanmethylation27
(HM27) DNA Analysis BeadChip by Illumina follow-
ing the manufacturer’s recommended protocol. Using
this platform, methylation levels were determined for
27,578 CpG dinucleotides spanning 14,495 genes in
each of the 100 test samples. The resulting data were
background normalized using Bead Studio. Correla-
tion coefficients of the two replicated samples were
0.81 and 0.89, respectively. The average beta value for
the methylated controls was 0.93 and the correlation
0.96. The average beta value and correlation of un-
methylated controls were 0.17 and 0.98, respectively.
Methylationmicroarray data were validated via pyrose-
quencing and DNA sequencing of a subset of individ-
uals tested on the original microarray and are reported
in detail elsewhere [16].
2.5. Analyses
We assembled a list of the genes (n = 33; Table 1)
identified as significantly differentially expressed be-
tween those with vs. without PTSD in whole blood
based on two previous studies [18,19]. Genes were in-
cluded in the list if they showed PTSD-associated dif-
ferences in gene expression in either of the two stud-
ies [18,19] and were also represented on the HM27
BeadChip. We then tested for potential main and inter-
action effects between methylation at CpG sites associ-
ated with these 33 loci and number of potentially trau-
matic events on risk of PTSD. Data were analyzed us-
ing R v2.10.0 and SAS v9.2. Initially, bivariate associ-
ations were assessed for PTSD and each of the variables
of interest. All tests were two-tailed and evaluated at
the 5% significance level. Main effects and interaction
effects models were then fitted to establish the relation-
ships of the predictors to PTSD. PTSD diagnosis was
based on the DSM-IV criteria as implemented by the
PCL-C (and additional questions) as described in the
previous section; the predicted probability of lifetime
PTSD was then modeled using logistic regression using
the following equation:
logit[P (Yi = 1)] =
α + β′Xi + γPTEi ∗ Methylationi
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Table 1
Genes investigated in the current study
Gene name Reference Expression level Reference
sequence∗ in those with vs. paper
without PTSD
MANNOSIDASE, ALPHA, CLASS 2C, MEMBER 1 NM006715 Higher [18]
DEAD (ASP-GLU-ALA-ASP) BOX POLYPEPTIDE 17 NM006386 Higher [18]
N-ACYLSPHINGOSINE AMIDOHYDROLASE (ACID CERAMIDASE) 1 NM177924 Lower [18]
FK506 BINDING PROTEIN 5 NM 004117 Lower [18]
CYCLIN D3 NM 001760 Lower [18]
NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE NM012343 Lower [18]
CHROMOSOME 2 OPEN READING FRAME 34 NM024766 Lower [18]
BRIDGING INTEGRATOR 1 NM 004305 Lower [18]
SIGNAL TRANSDUCER ACTIVATOR OF TRANSCRIPTION 5B NM012448 Lower [18]
TIA1 CYTOTOXIC GRANULE-ASSOC RNA BINDING PROTEIN NM022037 Lower [18]
CGG TRIPLET REPEAT BINDING PROTEIN 1 NM003663 Lower [18]
ENDOPLASMIC OXIDOREDUCTIN-1-LIKE PROTEIN NM014584 Lower [18]
METHYLTRANSFERASE LIKE 7A NM 014033 Lower [18]
RIBOSOMAL PROTEIN S6 KINASE, 90KDA, POLYPEPTIDE 5 NM004755 Lower [18]
INSULIN-LIKE GROWTH FACTOR 2 NM 000612 Higher [17]
CXCR1 CHEMOKINE (C-X-C MOTIF) RECEPTOR 1 (IL-8 RECEPTOR ALPHA) NM 000634 Higher [17]
INTEGRIN BETA 4 NM 001005619 Higher [17]
SOLUTE CARRIER FAMILY 1 (HIGH-AFFINITY ASPARTATE/GLUTAMATE
TRANSPORTER), MEMBER 6
NM 005071 Higher [17]
LYSOPHOSPHATIDIC ACID RECEPTOR 2 (EDG4) NM 004720 Higher [17]
COLONY-STIMULATING FACTOR 2 RECEPTOR, BETA, LOW-AFFINITY
(GRANULOCYTE-MACROPHAGE)
NM 000395 Lower [17]
THIOREDOXIN REDUCTASE 1 (TXR 1) NM 182729 Lower [17]
INTERLEUKIN 18 (INTERFERON-GAMMA-INDUCING FACTOR) (IL-18) NM 001562 Lower [17]
CHEMOKINE (C-C MOTIF) RECEPTOR 1 NM 001295 Lower [17]
PHOSPHOGLYCERATE DEHYRDROGENASE (3-PGDH) NM 006623 Lower [17]
CASEIN KINASE 1, GAMMA 3 NM 004384 Lower [17]
CASPASE 2, APOPTOSIS-RELATED CYSTEINE PEPTIDASE NM001224 Lower [17]
SUPEROXIDE DISMUTASE 1, SOLUBLE (SOD 1) NM 000454 Lower [17]
CD247 MOLECULE (CD 3Z) NM 000734 Lower [17]
INTERLEUKIN 16 (LYMPHOCYTE CHEMOATTRACTANT FACTOR) (IL-16) NM 004513 Lower [17]
SPHINGOSINE-1-PHOSPHATE RECEPTOR 1 (EDG1) NM 001400 Lower [17]
G-PROTEIN-COUPLED RECEPTOR 65 NM 003608 Lower [17]
CALNEXIN NM 001746 Lower [17]
CD 81 MOLECULE NM 004356 Lower [17]
If the official gene name currently differs from that presented in the original paper, the earlier name (or symbol) is provided parenthetically, in
italic font.
∗Where more than one RefSeq applies to a single gene, only one repr sentative RefSeq is shown (corresponding to the RefSeqthat was analyzed
in this study).
Where i represents an individual,Y is lifetime PTSD,
α is the intercept,β is a vector of regression coeffi-
cients, and X is a vector of covariates for each indi-
vidual,γ is the regression coefficient of the interaction
term, PTE*Methylation represents the interaction be-
tween number of PTEs and Methylation level at a CpG
site corresponding to one of the 33 candidate genes.
Continuous variables such as age, PBMC count, num-
ber of potentially traumatic events (PTE), and methy-
lation beta values were centered to the mean. All pre-
dictor variables were maintained in all the models for
consistency. Estimated coefficients were evaluated at
α = 0.05.
3. Results
Among the 33 loci identified as showing differen-
tial gene expression in whole blood between those with
vs. without PTSD [18,19], only one demonstrated a
significant (p = 0.04) methylation x PTE interaction
on risk of PTSD: mannosidase, alpha, class 2C, mem-
ber 1(MAN2C1), which showed this effect at CpG site
cg04008455 on the HM27 BeadChip. Table 2 presents
the descriptive statistics and bivariate associations for
the whole sample and for those with vs. without lifetime
PTSD for the variables included in our finalMAN2C1
model. Table 2a classifies the 19 PTEs assessed by the
study survey into four main trauma types and provides
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Table 2
Descriptive statistics and bivariate comparisons of participants with vs. without lifetime PTSD
PTSD
Without (n = 77) With (n = 23) Test
n/mean %/sd n/mean %/sd n/mean %/sd p
MAN2C1 methylation beta value 0.38 0.15 0.37 0.15 0.39 0.13 0.59
Number of Potentially traumatic events 6.04 3.60 5.58 3.48 7.57 3.65 0.02
Age 45.32 16.78 44.91 17.29 46.70 15.19 0.66
High SES 86 86.0 67 87.01 19 82.61 0.73
Female 60 60.0 45 58.44 15 65.22 0.56
Race= White 14 14.0 10 12.99 4 17.39 0.79∗
Race= Black 79 79.0 62 80.52 17 73.91 –
Race= Other 7 7.0 5 6.49 2 8.70 –
Ever Drink 77 77.0 60 77.92 17 73.91 0.69
Ever Smoke 58 58.0 41 53.25 17 73.91 0.08
PBMC 23.34 8.05 23.35 8.31 23.29 7.25 0.97
Any Medication 48 48.0 36 46.75 12 52.17 0.65
∗global 2× 3 chi-square test.
Table 2a
Descriptive statistics and bivariate comparisons of traumtype among those with vs. without lifetime PTSD
PTSD
Without (n = 77) With (n = 23) Test
n/mean %/sd n/mean %/sd n/mean %/sd p
Number of Potentially traumatic events 6.04 3.60 5.58 3.48 7.57 3.65 0.02
Assaultive violence 68 68.0 48 62.3 20 87.0 0.04
Other injury or shocking event 79 79.0 58 75.3 21 91.3 0.14
Learning about traumas to others 73 73.0 54 70.1 19 82.6 0.29
Sudden, unexpected death of close friend or relative 88 88.0 66 85.7 22 95.7 0.29
information regarding their prevalence in the overall
sample, and among those with vs. without lifetime
PTSD. The average age of the study sample was ap-
proximately 45 years, a majority of participants were
female (60%), African-american (79%) and had at-
tained high school equivalency or greater (86%). When
analyzed according to PTSD status, those with vs. with-
out the disorder differed significantly on the number
of PTEs to which they had been exposed, with those
with PTSD showing a higher average number of PTEs
than those without (7.57 vs. 5.58;p = 0.02). In ad-
dition, a greater proportion of participants with PTSD
reported having ever smoked (73.91% vs. 53.25%), al-
though this difference did not reach statistical signifi-
cance (p = 0.08). The remaining variables included in
the final model did not differ appreciably between the
two groups (Table 1).
Table 3 presents the results of our logistic regres-
sion main effects and interaction models focused on
MAN2C1. In the main effects model, having ever
smoked significantly increased risk of PTSD (OR 5.18,
95% CI: 1.26, 21.26,p = 0.02). In addition, exposure
to greater numbers of PTEs was associated with a sig-
nificant increase risk of PTSD, (OR= 1.21, 95% CI:
1.03, 1.42,p = 0.02), mirroring the results observed
in bivariate associations (Table 1). In contrast, having
ever drank appeared to protect against PTSD (OR 0.22,
95% CI: 0.05, 0.97,p = 0.05). No other factors showed
a significant association with risk of PTSD in the main
effects model (Table 2). Interaction models showed
similar significant associations on risk of PTSD as main
effects model. In addition, the interaction term was
significant: those with both higherMAN2C1methyla-
tion beta values and greater exposure to PTEs showed
a marked increase in risk of lifetime PTSD (OR 4.35,
95% CI: 1.07, 17.77,p = 0.04), confirming that methy-
lation levels at this locus modify cumulative traumat-
ic burden on risk of lifetime PTSD. These results are
depicted graphically in Fig. 1.
4. Discussion
The goal of this work was to assess epigenetic sig-
natures of PTSD among loci that had previously been
implicated in gene expression differences associated
with this disorder. Our results demonstrate that among
the 33 loci identified in previous work as being asso-
ciated with PTSD based on gene expression levels as-
sessed in peripheral whole blood,only one –MAN2C1–
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Table 3
Effect of MAN2C1methylation and number of traumatic events on risk of lifetime PTSD
Main effects model Interaction effect model
OR 95% CI p OR 95% CI p
MAN2C1 methylation beta value 1.71 0.03 90.38 0.79 0.31 0.0032.38 0.62
PTE 1.21 1.03 1.42 0.02 1.25 1.03 1.52 0.02
Age 1.00 0.96 1.03 0.79 0.99 0.95 1.03 0.62
High SES 0.81 0.19 3.43 0.78 0.83 0.19 3.66 0.81
Female 1.99 0.59 6.66 0.27 1.81 0.50 6.63 0.37
Race= Black 0.38 0.07 2.00 0.25 0.31 0.05 1.89 0.20
Race= Other 0.26 0.02 3.17 0.29 0.17 0.01 3.08 0.23
Ever Drink 0.22 0.05 0.97 0.05 0.22 0.05 0.94 0.04
Ever Smoke 5.18 1.26 21.26 0.02 4.84 1.14 20.54 0.03
PBMC 0.98 0.91 1.05 0.56 0.98 0.92 1.05 0.59
Any Medication 0.79 0.25 2.51 0.69 0.95 0.29 3.08 0.93
MAN2C1∗ PTE – – – – 4.35 1.07 17.77 0.04
Fig. 1. Risk of lifetime PTSD according toMAN2C1methylation beta value and number of potentially traumaticevents (PTEs). Shown are the
log odds of lifetime PTSD given 3, 6, 9, and 12 PTEs across increasing methylation values forMAN2C1.
showed evidence of a significant interaction with num-
ber of potentially traumatic events in predicting risk of
PTSD. Notably, this interaction was detected for the
locus showing the greatest fold change with respect to
differential expression between those with vs. without
PTSD in an earlier study (Fig. 2; [19]); yet prior to
that work, the gene had not been implicated in PTSD
etiology. Few studies exist that focus specifically on
MAN2C1. Nevertheless, the locus is known to be in-
volved in cancer progression, as its expression appears
to modulate tumor growth inin vivo [29,30] experi-
ments. In addition, bothin vitro [31,32] andin vi-
vo [32] work has implicatedMAN2C1in T-cell func-
tioning, and yeast two hybrid assays have shown that it
interacts with an immune-system related gene, HLA-
B associated transcript 2 (BAT2) [33]. Both gene ex-
pression [17–19] and methylation [16] studies of PTSD
have indicated that dysregulation in immune system re-
lated genes in peripheral blood are associated with this
disorder. Together with these earlier gene expression
results, our study provides additional, specific evidence
of this immune-related gene’s importance in develop-
ing PTSD, and suggests more generally that both gene
expression and epigenetic changes at specific loci are
associated with this disorder.
Our detection of a significant interaction between
MAN2C1methylation and participants’ exposure to po-
tentially traumatic events adds to a small but growing
literature examining the joint and interacting ways in
which molecular factors and cumulative traumatic bur-
den may modify risk for PTSD. Recent work by Ko-
lassa and colleagues [34,35] has focused on survivors
of the Rwandan genocide and risk for PTSD in light
of genetic variation at two distinct loci: the serotonin
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Fig. 2. Gene expression values ofMAN2C1among those with (n = 15) vs. without (n = 20) PTSD in [19]. Figure is adapted from data presented
in Table 2 of [19].∗∗ = p < 0.01 PTSD vs. control.
transporter (SLC6A4) locus [34] and the catechol-O-
methyltransferase (COMT) locus [35]. Although the
prevalence of PTSD approached 100% when traumat-
ic exposure reached extreme levels in both studies,
those homozygous for the shortSLC6A4promoter al-
lele showed 100% probability of PTSD independent of
number of traumatic events [34]; and those homozy-
gous for the MetCOMT allele showed a high risk of
PTSD even with small traumatic loads [35]. These
results suggest that molecular variation can moderate
risk for PTSD among those exposed to similar num-
bers of traumatic events. Results presented here add
a new dimension to these findings, in that the molec-
ular variation under consideration is methylation lev-
el, rather than genotype: at low levels ofMAN2C1
methylation, there appears to be little variation in risk
for PTSD among those exposed to lower vs. higher
numbers of PTEs (Fig. 1); at higherMAN2C1methy-
lation levels, however, the risk of PTSD is exponential-
ly higher among those with greater numbers of PTEs.
Still unknown is the role that both genetic and gene
expression variation play in moderating risk of PTSD
at this locus. Future work considering the combined
and interacting effects of genetic, epigenetic, and gene
expression variation on risk for PTSD are warranted.
It is notable that the remaining 32 loci implicated in
the two gene expression studies examined in this work
did not demonstrate significant methylation x PTE in-
teractions in predicting risk of PTSD. These results
raise the possibility that epigenetic modifications may
not play a substantial role in the molecular biology of
PTSD; however, since power may have been an issue
in this study (discussed further in the limitations sec-
tion below), additional work with larger samples will
be required to evaluate this hypothesis. Equally like-
ly is the possibility that we may have missed assess-
ing methylation at CpG sites relevant to gene func-
tion by relying on CpG sites represented on the HM27
BeadChip. More specifically, within any single gene,
methylation of some CpG sites may be unimportant to
gene function and thus lack relevance to the phenotype
under investigation. For example, in the focused study
of SLC6A4methylation differences associated with de-
pressive symptoms discussed in the introduction,in vit-
ro expression analyses showed that partial methylation
of just four targeted sites within the promoter region
of this gene was adequate to reduce gene expression
to levels obtained through complete methylation of the
entire promoter region [12]. These results suggest that
methylation of the remaining CpG sites in the promot-
er is unrelated to gene function. Notably, in this ex-
ample, there was no association observed between the
four gene expression-relevant CpG sites and depres-
sion [12], emphasizing the complexity of pinpointing
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gene-expression relevant epigenetic signatures that are
also relevant to complex mental illness.
Furthermore, epigenetic regulation of gene expres-
sion is a complex biological phenomenon that is still
being worked out in basic biological studies. In gen-
eral, methylation and gene expression are typically be-
lieved to show an inverse correlation, such that in-
creased methylation corresponds to decreased gene ex-
pression and vice-versa. Recent work, however, has
demonstrated a more complicated picture. A genome-
wide assessment of quantitative trait loci (QTL) that as-
sessed SNP variation in association with either methy-
lation or gene expression QTLs showed that, in contrast
to the classical prediction of an inverse correlation be-
tween methylation and gene expression patterns at spe-
cific loci, almost half of the significant methQTLs and
expression QTLs correlated in the same direction [36];
however, when joint meth-and expression QTLs in-
volved a methylation site falling within a CpG island –
which occurred in only a minority of cases – the classi-
cal inverse pattern was observed [36]. On a more clin-
ically relevant note, the genome-wide scan of methyla-
tion differences in the rat model of PTSD discussed in
the introduction identified four total genes that showed
PTSD-associated methylation differences [15]; howev-
er, only one–Dlgap2–showed altered gene expression
between rats with vs. without PTSD-like phenotypes.
Thus, just as some loci show PTSD-associated methy-
lation, but not gene expression, differences, the con-
verse is also true: there are likely to be genes that show
PTSD-associate gene expression, but not methylation,
differences.
Our study must be interpreted in light of a number
of limitations. First, although we were able to iden-
tify PTSD-associated epigenetic signatures in genes
previously implicated in PTSD dysregulation via gene
expression studies, the ideal study would pair gene
expression and methylation (or other epigenetic) data
from the same individuals, in order to more robustly as-
sess the correspondance between gene expression and
methylation data with respect to PTSD. Studies to ad-
dress this issue are currently underway. Second, in re-
lying upon previous studies of gene expression data, we
recognize that the analytic approaches used to identify
differentially expressed genes differed between studies,
such that the candidate gene list we used to investigate
PTSD-associated epigenetic differences was arrived at
by heterogeneous methods. In addition, by constrain-
ing our inquiry only to genes that have been implicated
in whole blood-derived gene expression studies, we are
undoubtedly missing other epigenetic signatures rele-
vant to this disorder that have been implicated in oth-
er work (i.e. genotype-based candidate gene studies in
humans and animal models of PTSD, e.g. [6,15]). We
thus consider our approach to be only an initial, limit-
ed assessment of epigenetic signatures associated with
this disorder. Third, although one of the two gene ex-
pression studies was genome-wide [19], the epigenetic
study with which it was paired in this work assessed
methylation levels at only 14,500 genes – the largest
number available to assess via microarray to date, but
not completely genome-wide in coverage. As such, we
could not analyse some loci that were represented on
the HG U133 Plus2 Array but not on the HM27 Bead-
chip (e.g.HLA-DRB1, TMEM167A). Fourth, although
we included 100 individuals with and without lifetime
PTSD – greater than the number assessed in either of
the gene expression studies – we were likely underpow-
ered to detect methylation x PTE interactions at some
of the candidate genes tested in this study. Although the
optimal sample size for epigenomic studies is current-
ly unknown [37], our own estimates suggest that our
power to detect an interaction in this study was roughly
0.24, far lower than the typical study ideal of 0.8 or
greater. Finally, although we did detect a significant
interaction forMAN2C1, the p value did not meet the
criteria for statistical significance when accounting for
our multiple comparisons across genes. Nevertheless,
the p value far exceeds the more liberal p-value cutoffs
(p < 0.2) sometimes adopted for G x E interactions
(e.g. [38]). Replication studies are clearly needed in
order to address these several study limitations.
Despite these limitations, our work takes a first step
towards demonstrating that coordinated gene expres-
sion and epigenetic changes may offer potential molec-
ular signatures of increased risk for and resilience to this
disorder. Our primary result stemming directly from
the analyses conducted in this work – thatMAN2C1
methylation level modifies traumatic burden to predict
risk of lifetime PTSD – also helps to shed light on the
biological correlates of individual differences, thereby
helping to explain why some people develop PTSD in
the face of exposure to PTEs, while others do not [4,
24]. Ongoing work assessing genotype, gene expres-
sion, and methylation differences between individuals
with vs. without this disorder should provide a more
robust characterization of the molecular variation un-
derlying phenotypic variation following PTE exposure
atMAN2C1and other loci.
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